Femtosecond-assisted LASIK with and without mitomycin C performed to correct hyperopia: a 15-month follow-up

ESCRS 2015 - Femtosecond-assisted LASIK with and without mitomycin C performed to correct hyperopia: a 15-month follow-up

Firts Author: M. García-González

Co Author(s): M. Iglesias Iglesias, J. Sanchez-Pina, P. Drake, M. Teus

 

Purpose:

To compare the 15-month postoperative visual and refractive results of FemtoLASIK with and without the adjuvant use of mitomycin C (MMC), to correct hyperopia.

 

Setting:

Clinica Novovision, Madrid, Spain Clinica Rementeria, Madrid, Spain Hospital Universitario Príncipe de Asturias, Alcala de Henares, Madrid.

 

Methods:

One hundred fifty-two consecutive eyes were divided in two groups: eyes in which 0.02% MMC was applied for five seconds over the ablated stroma (MMC-group) and without MMC (non-MMC group). We compared the visual and refractive results between groups at the 15-month postoperative visit.


 

Results

76 eyes were included in each group. No significant differences were found between groups in the postoperative uncorrected distance visual acuity, postoperative corrected distance visual acuity, residual refraction, postoperative keratometry or residual central corneal thickness. The incidence of retreatments during the 15-month follow-up was significantly lower in the MMC-group (6.58%) compared to the non-MMC group (10.53%) (P=0.01).

 

Conclusions

FemtoLASIK performed to correct hyperopia, regardless of the use of MMC, seems to provide good visual and refractive outcomes in a 15-month follow-up. However, the use of MMC when performing FemtoLASIK to correct hyperopia seems to reduce the incidence of retreatments.

 

Última modificación de la web: 10 July 2017